Neoplasia/BPH

	Survival Outcomes of a Smoking Cessation Treatment Program After Diagnosis of Bladder Cancer. Eur Urol Oncol MacDonald LP, Kypriotakis G, Karam-Hage M, Minnix JA, Beneventi D, Cui Y, Blalock JA, Robinson JD, Alhalabi O, Hassanazadeh CJ, Lee BH, Navai N, Kamat AM, Dinney CP, Cinciripini PM, Bree KK. PMID: 42236415 [PubMed - as supplied by publisher]
	Re: Khan S, Papa N, Kneebone A, et al. Prospective Comparison of (64)Copper [(64)Cu]SAR-bisPSMA vs (68)Gallium[(68)Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial). Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.001. Eur Urol Ding G, Wang J, Wu J. PMID: 42236390 [PubMed - as supplied by publisher]
	Integration of PSMA PET into the New Recommendations from Prostate Cancer Working Group 4 for Prostate Cancer Trials. J Nucl Med Technol Kuo PH, Morris MJ. PMID: 42235999 [PubMed - in process]
	Prostate cancer: All black men aged 45-74 will be offered screening in major trial expansion. BMJ Iacobucci G. PMID: 42235994 [PubMed - in process]
	Electrochemical biosensor-based strategies for sensitive detection of prostate cancer biomarkers. Clin Chim Acta Saha A, Sharma K. PMID: 42235733 [PubMed - as supplied by publisher]
	Diagnostic Delay Duration and Determinants in Hereditary Leiomyomatosis and Renal Cell Cancer: An Observational Study. J Am Acad Dermatol Udupa M, Bendayan E, Allen-Flanagan T, Gunyon M, Alamari A, Ouchene L, Marino TC, Kaouache M, Rahme E, Foulkes WD, Netchiporouk E. PMID: 42235607 [PubMed - as supplied by publisher]
	Explainable artificial intelligence in prostate cancer treatment recommendation: A decision support system for oncological expert panels. Eur J Cancer Duwe G, Mercier D, Kauth V, Jost LM, Moench K, Rajashekar V, Junker M, Neumann CCM, Dengel A, Haferkamp A, Höfner T. PMID: 42235465 [PubMed - as supplied by publisher]
	Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review. Eur J Cancer Ahrens M, Haanen J, Albiges L, Goupil MG, Boleti E, Gravis G, Fléchon A, Grimm MO, Bedke J, Barthélémy P, Castellano D, Mellado B, Ivanyi P, Rottey S, Flörcken A, Suárez C, Maroto JP, Grünwald V, Oosting S, Kopecky J, Zschäbitz S, Boegemann M, Buchler T, Niegisch G, Goebell PJ, Waddell T, Joly F, Priou F, Retz M, Siemer S, Zimmermann U, Deckbar D, Burkholder I, Hartmann A, Bergmann L, Interdisciplinary Renal Cell Carcinoma Working Group of the DKG (IAGN). PMID: 42235464 [PubMed - as supplied by publisher]
	Evolution of PSMA-GRPr heterobivalent radiolabeled conjugates for the diagnosis and therapy of prostate cancer. Eur J Med Chem Grigoriev GP, Beloglazkina EK, Petrov SA. PMID: 42235186 [PubMed - as supplied by publisher]
	Collecting electronic patient-reported outcomes via smartphone text messages in a bladder cancer RCT: A feasibility study. Urol Oncol Munk L, Kumarasegaram V, Hyldgaard JM, Jensen JB, Graugaard-Jensen C, Lindgren MS. PMID: 42235120 [PubMed - as supplied by publisher]
	Effects of exercise on sexual activity and sexual dysfunction in patients with prostate cancer: a systematic review and meta-analysis. J Sex Med Wen Z, Ding F, Ma X, Zhu Y. PMID: 42234465 [PubMed - in process]
	Spectral CT in renal cell carcinoma: the promising role of dual-energy and photon-counting techniques. Abdom Radiol (NY) Kekelidze M, García-Figueiras R, Kolmos M, Silberbrandt AR, Olech WE, Borgbjerg J, , Flohr T, Alkadhi H, Mirón Mombiela R. PMID: 42234111 [PubMed - as supplied by publisher]
	Toxicity and risk after using new modalities of radiotherapy in Algeria: retrospective intercomparison study. Radiat Prot Dosimetry Boughalia A, Fellah M, El Ghribi Z, Oukrif S. PMID: 42233309 [PubMed - indexed for MEDLINE]
	Ferroptosis and prostate cancer: A translational path from molecular mechanisms to precision therapy. Genes Dis Huang Y, Ma Y, He J, Song T. PMID: 42233093 [PubMed]
	Polish Brachytherapy Society clinical recommendations and expert consensus on radical high-dose-rate brachytherapy for prostate cancer. J Contemp Brachytherapy Chyrek AJ, Hetna, Kukie, Lelek P, Kluska A, Romaniszyn A, Samo, Burchardt W, Cisek P, Krzysztofiak T, Kolbusz M, Kazalski D, Filipowski T, Kazberuk D, Szmigiel-Trzcin'ska A, Celarek K, Madej P, Konat-Ba Ska K, Lichon' K, Matys R, Bilski M, Burchardt E, Stankiewicz M, Chiche, Wojcieszek P. PMID: 42232852 [PubMed]
	Precision Diagnostics in Prostate Cancer Treatment (PREDICT): A Phase II Multiarm Biomarker-Based Study (Alliance A032102). JCO Oncol Adv Chen YW, Bobek O, Heller G, Berg S, Tan A, Zhao SG, Galsky M, Rosenberg J, Beltran H, McKay RR. PMID: 42232816 [PubMed]
	Insights from a rare case of eosinophilic solid and cystic renal cell carcinoma: Diagnostic highlights and therapeutic directions. Urol Case Rep Qiu J, Ni L, Yu L, Yang Y. PMID: 42232815 [PubMed]
	Segmentation regularized training for multi-domain deep learning registration applied to magnetic resonance-guided prostate cancer radiotherapy. Phys Imaging Radiat Oncol Madhavan S, Gui C, Bosma L, Simeth J, Jiang J, Côté N, Rezaeian NH, Nagar H, Brennan V, Tyagi N, Veeraraghavan H. PMID: 42232230 [PubMed]
	The efficacy and safety of darolutamide combination therapy in advanced prostate cancer: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol Cao X, Li D, Han Z, Li Z, Chu J, Song C, Huang H, Yuan H, Wang Z. PMID: 42232182 [PubMed]
	GWAS from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer. EJNMMI Res Tanegashima T, Shiota M, Doi A, Tatarano S, Kamba T, Igawa T, Masumori N, Uemura H, Kamoto T, Higashijima K, Mitsunari K, Uemura H, Sumiyoshi T, Isoda T, Ishigami K, Tokunaga S, Eto M. PMID: 42230449 [PubMed - as supplied by publisher]

Articles 1 - 20 / 188326

Page 1 of 9417



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy